{"id":"W2082809017","doi":"10.1111/j.1463-1326.2007.00753.x","title":"Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes","year":2007,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Diabetes Canada; Canadian Diabetes Association; American Diabetes Association","keywords":"Medicine; Rosiglitazone; Glimepiride; Regimen; Internal medicine; Fixed-dose combination; Adiponectin; Type 2 diabetes; Adverse effect; Gastroenterology; Clinical endpoint; Diabetes mellitus; Pharmacology; Endocrinology; Insulin resistance; Insulin; Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009949537,0.0006815237,0.002779051,0.0004012492,0.0004584525,0.0007310734,0.000717659,0.0008362433,0.0025155],"category_scores_gemma":[0.001662335,0.0004286779,0.001042326,0.0004744335,0.0003451803,0.0004222969,0.0002365938,0.001512276,0.0004673893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007187976,"about_ca_system_score_gemma":0.0005977591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009385057,"about_ca_topic_score_gemma":0.003106266,"domain_scores_codex":[0.9994203,0.0002115684,0.0000668604,0.0001284494,0.0001126445,0.00006027317],"domain_scores_gemma":[0.9991667,0.0002038004,0.0002187535,0.00005379453,0.00005692412,0.0002999694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5420775,0.01703427,0.06353188,0.001658405,0.00514232,0.0006674241,0.0002558363,0.002070906,0.02247137,0.00009929432,0.002581534,0.3424092],"study_design_scores_gemma":[0.2379926,0.4080181,0.3329405,0.0003936466,0.004450199,0.00180221,0.0001840123,0.002304995,0.00439505,0.0001643535,0.007250378,0.0001039621],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853289,0.01151943,0.0002865678,0.0002605413,0.000160884,0.0003661822,0.0002579409,0.00008106445,0.001738374],"genre_scores_gemma":[0.9942632,0.002748529,0.0007914613,0.0005340849,0.0002185434,0.0002670481,0.000575079,0.000009250185,0.0005926793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002779051,"threshold_uncertainty_score":0.008415163,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006522453057879444,"score_gpt":0.2174371093316265,"score_spread":0.2109146562737471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}